Top

Published in:

Open Access 01-12-2024 | Neonatal Screening | Review

Application of tandem mass spectrometry in the screening and diagnosis of mucopolysaccharidoses

Authors: Jing-Wen Li, Shao-Jia Mao, Yun-Qi Chao, Chen-Xi Hu, Yan-Jie Qian, Yang-Li Dai, Ke Huang, Zheng Shen, Chao-Chun Zou

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Abstract

Mucopolysaccharidoses (MPSs) are caused by a deficiency in the enzymes needed to degrade glycosaminoglycans (GAGs) in the lysosome. The storage of GAGs leads to the involvement of several systems and even to the death of the patient. In recent years, an increasing number of therapies have increased the treatment options available to patients. Early treatment is beneficial in improving the prognosis, but children with MPSs are often delayed in their diagnosis. Therefore, there is an urgent need to develop a method for early screening and diagnosis of the disease. Tandem mass spectrometry (MS/MS) is an analytical method that can detect multiple substrates or enzymes simultaneously. GAGs are reliable markers of MPSs. MS/MS can be used to screen children at an early stage of the disease, to improve prognosis by treating them before symptoms appear, to evaluate the effectiveness of treatment, and for metabolomic analysis or to find suitable biomarkers. In the future, MS/MS could be used to further identify suitable biomarkers for MPSs for early diagnosis and to detect efficacy.

Arunkumar N, Langan TJ, Stapleton M, Kubaski F, Mason RW, Singh R, Kobayashi H, Yamaguchi S, Suzuki Y, Orii K, Orii T, Fukao T, Tomatsu S. Newborn screening of mucopolysaccharidoses: past, present, and future. J Hum Genet. 2020a;65(7):557–67. https://doi.org/10.1038/s10038-020-0744-8.CrossRefPubMed

Arunkumar N, Langan TJ, Stapleton M, Kubaski F, Mason RW, Singh R, Kobayashi H, Yamaguchi S, Suzuki Y, Orii K, Orii T, Fukao T, Tomatsu S. Newborn screening of mucopolysaccharidoses: past, present, and future. J Hum Genet. 2020b;65(7):557–67. https://doi.org/10.1038/s10038-020-0744-8.CrossRefPubMed

Arunkumar N, Vu DC, Khan S, Kobayashi H, Can N, Oguni TB, Watanabe T, Tanaka J, Yamaguchi M, Taketani S, Ago T, Ohnishi Y, Saikia H, Álvarez S, J. V., Tomatsu S. Diagnosis of mucopolysaccharidoses and mucolipidosis by Assaying Multiplex Enzymes and glycosaminoglycans. Diagnostics (Basel Switzerland). 2021;11(8):1347. https://doi.org/10.3390/diagnostics11081347.CrossRefPubMed

Auray-Blais C, Collerette-Tremblay J, Lavoie P. UPLC–MS/MS analysis of keratan sulfate from urine samples collected on filter paper for monitoring & follow-up of Morquio A patients. Bioanalysis. 2018;10(15):1181–92. https://doi.org/10.4155/bio-2018-0064.CrossRefPubMed

Auray-Blais C, Lavoie P, Tomatsu S, Valayannopoulos V, Mitchell JJ, Raiman J, Beaudoin M, Maranda B, Clarke JTR. UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses. Anal Chim Acta. 2016;936:139–48. https://doi.org/10.1016/j.aca.2016.06.054.CrossRefPubMed

Baydakova G, Ilyushkina A, Gaffke L, Pierzynowska K, Bychkov I, Ługowska A, Wegrzyn G, Tylki-Szymanska A, Zakharova E. Elevated LysoGb3 concentration in the neuronopathic forms of Mucopolysaccharidoses. Diagnostics (Basel Switzerland). 2020;10(3):155. https://doi.org/10.3390/diagnostics10030155.CrossRefPubMed

Benetó N, Vilageliu L, Grinberg D, Canals I. Sanfilippo Syndrome: molecular basis, Disease models and therapeutic approaches. Int J Mol Sci. 2020;21(21):E7819. https://doi.org/10.3390/ijms21217819.CrossRef

Bhalla A, Ravi R, Fang M, Arguello A, Davis SS, Chiu C-L, Blumenfeld JR, Nguyen HN, Earr TK, Wang J, Astarita G, Zhu Y, Fiore D, Scearce-Levie K, Diaz D, Cahan H, Troyer MD, Harris JM, Escolar ML. Characterization of fluid biomarkers reveals lysosome dysfunction and neurodegeneration in Neuronopathic MPS II patients. Int J Mol Sci. 2020;21(15):5188. https://doi.org/10.3390/ijms21155188.CrossRefPubMedPubMedCentral

Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem. 2008;54(12):2067–70. https://doi.org/10.1373/clinchem.2008.115410.CrossRefPubMedPubMedCentral

10.

Bodamer OA, Giugliani R, Wood T. The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): a changing landscape. Mol Genet Metab. 2014;113(1–2):34–41. https://doi.org/10.1016/j.ymgme.2014.07.013.CrossRefPubMed

11.

Bronstein MG, Pan RJ, Dant M, Lubin B. Leveraging evidence-based Public Policy and Advocacy to Advance Newborn Screening in California. Pediatrics. 2019;143(2):e20181886. https://doi.org/10.1542/peds.2018-1886.CrossRefPubMed

12.

Brusius-Facchin AC, Malaga R, Leistner-Segal D, S., Giugliani R. Recent advances in molecular testing to improve early diagnosis in children with mucopolysaccharidoses. Expert Rev Mol Diagn. 2018;18(10):855–66. https://doi.org/10.1080/14737159.2018.1523722.CrossRefPubMed

13.

Burlina AB, Gragnaniello V. Newborn screening of mucopolysaccharidosis type I. Crit Rev Clin Lab Sci. 2022;59(4):257–77. https://doi.org/10.1080/10408363.2021.2021846.CrossRefPubMed

14.

Burlina AB, Polo G, Rubert L, Gueraldi D, Cazzorla C, Duro G, Salviati L, Burlina AP. Implementation of second-tier tests in newborn screening for lysosomal disorders in North Eastern Italy. Int J Neonatal Screen. 2019;5(2):24. https://doi.org/10.3390/ijns5020024.CrossRefPubMedPubMedCentral

15.

Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, Bembi B, Cazzorla C, Rubert L, Zordan R, Desnick RJ, Burlina AP. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018;41(2):209–19. https://doi.org/10.1007/s10545-017-0098-3.CrossRefPubMed

16.

Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, Schneider M, Grange DK, Nash C, Shryock H, Barnett R, Shao R, Basheeruddin K, Dizikes G. Newborn screening for Lysosomal Storage Disorders in Illinois: the initial 15-Month experience. J Pediatr. 2017;190:130–5. https://doi.org/10.1016/j.jpeds.2017.06.048.CrossRefPubMed

17.

Burton BK, Hoganson GE, Fleischer J, Grange DK, Braddock SR, Hickey R, Hitchins L, Groepper D, Christensen KM, Kirby A, Moody C, Shryock H, Ashbaugh L, Shao R, Basheeruddin K. Population-based newborn screening for mucopolysaccharidosis type II in Illinois: the First Year experience. J Pediatr. 2019;214:165–e1671. https://doi.org/10.1016/j.jpeds.2019.07.053.CrossRefPubMed

18.

Chan M-J, Liao H-C, Gelb MH, Chuang C-K, Liu M-Y, Chen H-J, Kao S-M, Lin H-Y, Huang Y-H, Kumar AB, Chennamaneni NK, Pendem N, Lin S-P, Chiang C-C. Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses types I, II, and VI. J Pediatr. 2019;205:176–82. https://doi.org/10.1016/j.jpeds.2018.09.063.CrossRefPubMed

19.

Chen X, Qiu W, Ye J, Han L, Gu X, Zhang H. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China. J Hum Genet. 2016;61(4):345–9. https://doi.org/10.1038/jhg.2015.155.CrossRefPubMed

20.

Chien Y-H, Lee N-C, Chen P-W, Yeh H-Y, Gelb MH, Chiu P-C, Chu S-Y, Lee C-H, Lee A-R, Hwu W-L. Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns. Orphanet J Rare Dis. 2020;15(1):38. https://doi.org/10.1186/s13023-020-1322-z.CrossRefPubMedPubMedCentral

21.

Chuang C-K, Lin H-Y, Wang T-J, Huang Y-H, Chan M-J, Liao H-C, Lo Y-T, Wang L-Y, Tu R-Y, Fang Y-Y, Chen T-L, Ho H-C, Chiang C-C, Lin S-P. Status of newborn screening and follow up investigations for mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13(1):84. https://doi.org/10.1186/s13023-018-0816-4.CrossRefPubMedPubMedCentral

22.

Chuang C-K, Tu Y-R, Lee C-L, Lo Y-T, Chang Y-H, Liu M-Y, Liu H-Y, Chen H-J, Kao S-M, Wang L-Y, Ho H-J, Lin H-Y, Lin S-P. Updated confirmatory diagnosis for mucopolysaccharidoses in Taiwanese infants and the application of Gene variants. Int J Mol Sci. 2022;23(17):9979. https://doi.org/10.3390/ijms23179979.CrossRefPubMedPubMedCentral

23.

Courtney E, Pickens CA, Cuthbert C, Petritis K. Multiplexing Iduronate-2-Sulphatase (MPS-II) into a 7-Plex lysosomal storage disorder MS/MS assay using Cold-Induced phase separation. Int J Neonatal Screen. 2023;9(2):32. https://doi.org/10.3390/ijns9020032.CrossRefPubMedPubMedCentral

24.

D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: one hundred years of Research, diagnosis, and treatment. Int J Mol Sci. 2020;21(4):E1258. https://doi.org/10.3390/ijms21041258.CrossRef

25.

Dorley MC, Dizikes GJ, Pickens CA, Cuthbert C, Basheeruddin K, Gulamali-Majid F, Hetterich P, Hietala A, Kelsey A, Klug T, Lesko B, Mills M, Moloney S, Neogi P, Orsini J, Singer D, Petritis K. Harmonization of Newborn Screening results for pompe disease and mucopolysaccharidosis type I. Int J Neonatal Screen. 2023;9(1):11. https://doi.org/10.3390/ijns9010011.CrossRefPubMedPubMedCentral

26.

Duffey TA, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Anal Chem. 2010;82(22):9587–91. https://doi.org/10.1021/ac102090v.CrossRefPubMedPubMedCentral

27.

Escolar ML, Jones SA, Shapiro EG, Horovitz DDG, Lampe C, Amartino H. Practical management of behavioral problems in mucopolysaccharidoses disorders. Mol Genet Metab. 2017;122:35–40. https://doi.org/10.1016/j.ymgme.2017.09.010.CrossRef

28.

Fachel FNS, Frâncio L, Poletto É, Schuh RS, Teixeira HF, Giugliani R, Baldo G, Matte U. Gene editing strategies to treat lysosomal disorders: the example of mucopolysaccharidoses. Adv Drug Deliv Rev. 2022;191:114616. https://doi.org/10.1016/j.addr.2022.114616.CrossRefPubMed

29.

Forni G, Malvagia S, Funghini S, Scolamiero E, Mura M, Della Bona M, Villanelli F, Damiano R, la Marca G. LC-MS/MS method for simultaneous quantification of heparan sulfate and dermatan sulfate in urine by butanolysis derivatization. Clin Chim Acta. 2019;488:98–103. https://doi.org/10.1016/j.cca.2018.11.001.CrossRefPubMed

30.

Hagemeijer MC, van den Bosch JC, Bongaerts M, Jacobs EH, van den Hout JMP, Oussoren E, Ruijter GJG. Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM mass spectrometry for screening of lysosomal storage disorders. J Inherit Metab Dis. 2023;46(2):206–19. https://doi.org/10.1002/jimd.12597.CrossRefPubMed

31.

Hall PL, Sanchez R, Hagar AF, Jerris SC, Wittenauer A, Wilcox WR. Two-tiered newborn screening with post-analytical tools for pompe disease and mucopolysaccharidosis type I results in performance improvement and future direction. Int J Neonatal Screen. 2020;6(1):2. https://doi.org/10.3390/ijns6010002.CrossRefPubMedPubMedCentral

32.

Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, Wesley J, McIvor RS. Mucopolysaccharidosis type I: a review of the Natural History and Molecular Pathology. Cells. 2020;9(8):1838. https://doi.org/10.3390/cells9081838.CrossRefPubMedPubMedCentral

33.

Harmatz P, Shediac R. Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment. Front Bioscience (Landmark Edition). 2017;22(3):385–406. https://doi.org/10.2741/4490.CrossRef

34.

He QQ, Trim PJ, Lau AA, King BM, Hopwood JJ, Hemsley KM, Snel MF, Ferro V. Synthetic disaccharide standards enable quantitative analysis of stored Heparan Sulfate in MPS IIIA Murine Brain regions. ACS Chem Neurosci. 2019;10(8):3847–58. https://doi.org/10.1021/acschemneuro.9b00328.CrossRefPubMed

35.

Heon-Roberts R, Nguyen ALA, Pshezhetsky AV. Molecular bases of Neurodegeneration and Cognitive decline, the Major Burden of Sanfilippo Disease. J Clin Med. 2020;9(2):E344. https://doi.org/10.3390/jcm9020344.CrossRef

36.

Heywood WE, Camuzeaux S, Doykov I, Patel N, Preece R-L, Footitt E, Cleary M, Clayton P, Grunewald S, Abulhoul L, Chakrapani A, Sebire NJ, Hindmarsh P, de Koning TJ, Heales S, Burke D, Gissen P, Mills K. Proteomic Discovery and Development of a multiplexed targeted MRM-LC-MS/MS assay for urine biomarkers of Extracellular Matrix disruption in Mucopolysaccharidoses I, II, and VI. Anal Chem. 2015;87(24):12238–44. https://doi.org/10.1021/acs.analchem.5b03232.CrossRefPubMed

37.

Kadali S, Naushad SM, Rama Devi R, A., Bodiga VL. Biochemical, machine learning and molecular approaches for the differential diagnosis of Mucopolysaccharidoses. Mol Cell Biochem. 2019;458(1–2):27–37. https://doi.org/10.1007/s11010-019-03527-6.CrossRefPubMed

38.

Khaledi H, Gelb MH. Tandem Mass Spectrometry enzyme assays for Multiplex Detection of 10-Mucopolysaccharidoses in dried blood spots and fibroblasts. Anal Chem. 2020;92(17):11721–7. https://doi.org/10.1021/acs.analchem.0c01750.CrossRefPubMedPubMedCentral

39.

Khaliq T, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA. Clin Chem. 2011;57(1):128–31. https://doi.org/10.1373/clinchem.2010.149880.CrossRefPubMed

40.

Khan SA, Mason RW, Giugliani R, Orii K, Fukao T, Suzuki Y, Yamaguchi S, Kobayashi H, Orii T, Tomatsu S. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. Mol Genet Metab. 2018;125(1–2):44–52. https://doi.org/10.1016/j.ymgme.2018.04.011.CrossRefPubMedPubMedCentral

41.

Khan SA, Mason RW, Kobayashi H, Yamaguchi S, Tomatsu S. Advances in glycosaminoglycan detection. Mol Genet Metab. 2020;130(2):101–9. https://doi.org/10.1016/j.ymgme.2020.03.004.CrossRefPubMedPubMedCentral

42.

Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K, Burin MG, Rojas-Málaga D, Brusius-Facchin AC, Leistner-Segal S, Giugliani R. Diagnosis of Mucopolysaccharidoses. Diagnostics (Basel Switzerland). 2020;10(3):172. https://doi.org/10.3390/diagnostics10030172.CrossRefPubMed

43.

Kubaski F, Osago H, Mason RW, Yamaguchi S, Kobayashi H, Tsuchiya M, Orii T, Tomatsu S. Glycosaminoglycans detection methods: applications of mass spectrometry. Mol Genet Metab. 2017;120(1–2):67–77. https://doi.org/10.1016/j.ymgme.2016.09.005.CrossRefPubMed

44.

Kubaski F, Sousa I, Amorim T, Pereira D, Trometer J, Souza A, Ranieri E, Polo G, Burlina A, Brusius-Facchin AC, Netto ABO, Tomatsu S, Giugliani R. Neonatal screening for MPS disorders in Latin America: a Survey of Pilot initiatives. Int J Neonatal Screen. 2020;6(4):90. https://doi.org/10.3390/ijns6040090.CrossRefPubMedPubMedCentral

45.

Kumar AB, Masi S, Ghomashchi F, Chennamaneni NK, Ito M, Scott CR, Turecek F, Gelb MH, Spacil Z. Tandem Mass Spectrometry has a larger Analytical Range than fluorescence assays of Lysosomal Enzymes: application to newborn screening and diagnosis of Mucopolysaccharidoses types II, IVA, and VI. Clin Chem. 2015;61(11):1363–71. https://doi.org/10.1373/clinchem.2015.242560.CrossRefPubMedPubMedCentral

46.

Lin H-Y, Lee C-L, Lo Y-T, Tu R-Y, Chang Y-H, Chang C-Y, Chiu PC, Chang T-M, Tsai W-H, Niu D-M, Chuang C-K, Lin S-P. An At-Risk Population Screening Program for mucopolysaccharidoses by measuring urinary glycosaminoglycans in Taiwan. Diagnostics (Basel Switzerland). 2019;9(4):140. https://doi.org/10.3390/diagnostics9040140.CrossRefPubMed

47.

Lin H-Y, Lee C-L, Lo Y-T, Wang T-J, Huang S-F, Chen T-L, Wang Y-S, Niu D-M, Chuang C-K, Lin S-P. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses. Mol Genet Genom Med. 2018;6(6):982–92. https://doi.org/10.1002/mgg3.471.CrossRef

48.

Lin H-Y, Lo Y-T, Wang T-J, Huang S-F, Tu R-Y, Chen T-L, Lin S-P, Chuang C-K. Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis. Sci Rep. 2019;9(1):10755. https://doi.org/10.1038/s41598-019-46829-x.CrossRefPubMedPubMedCentral

49.

Liu Y, Yi F, Kumar AB, Kumar Chennamaneni N, Hong X, Scott CR, Gelb MH, Turecek F. Multiplex Tandem Mass Spectrometry Enzymatic Activity Assay for Newborn Screening of the mucopolysaccharidoses and Type 2 neuronal ceroid lipofuscinosis. Clin Chem. 2017;63(6):1118–26. https://doi.org/10.1373/clinchem.2016.269167.CrossRefPubMedPubMedCentral

50.

Mak J, Cowan TM. Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry. Mol Genet Metab. 2021;134(1–2):43–52. https://doi.org/10.1016/j.ymgme.2021.08.006.CrossRefPubMedPubMedCentral

51.

Makower Å, Arnelöf E, Andersson T, Edlund P-O, Gustavsson S, Janson J, Gelius SS, Tjernberg A. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA. Bioanalysis. 2019;11(15):1389–403. https://doi.org/10.4155/bio-2019-0095.CrossRefPubMed

52.

Marsden D, Levy H. Newborn screening of lysosomal storage disorders. Clin Chem. 2010;56(7):1071–9. https://doi.org/10.1373/clinchem.2009.141622.CrossRefPubMed

53.

Mashima R, Ohira M, Okuyama T, Tatsumi A. Quantification of the enzyme activities of iduronate-2-sulfatase, N-acetylgalactosamine-6-sulfatase and N-acetylgalactosamine-4-sulfatase using liquid chromatography-tandem mass spectrometry. Mol Genet Metabolism Rep. 2018;14:36–40. https://doi.org/10.1016/j.ymgmr.2017.12.001.CrossRef

54.

Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S. Newborn screening for lysosomal storage disorders. Semin Perinatol. 2015;39(3):206–16. https://doi.org/10.1053/j.semperi.2015.03.005.CrossRefPubMed

55.

Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, Fuller M, Christensen E, Skovby F, Hopwood JJ. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004;114(4):909–16. https://doi.org/10.1542/peds.2004-0583.CrossRefPubMed

56.

Menkovic I, Marchand A-S, Boutin M, Auray-Blais C. Neonatal Mass urine Screening Approach for early detection of Mucopolysaccharidoses by UPLC-MS/MS. Diagnostics (Basel Switzerland). 2019;9(4):195. https://doi.org/10.3390/diagnostics9040195.CrossRefPubMed

57.

Minter Baerg MM, Stoway SD, Hart J, Mott L, Peck DS, Nett SL, Eckerman JS, Lacey JM, Turgeon CT, Gavrilov D, Oglesbee D, Raymond K, Tortorelli S, Matern D, Mørkrid L, Rinaldo P. Precision newborn screening for lysosomal disorders. Genet Medicine: Official J Am Coll Med Genet. 2018;20(8):847–54. https://doi.org/10.1038/gim.2017.194.CrossRef

58.

Nakamura K, Hattori K, Endo F. Newborn screening for lysosomal storage disorders. Am J Med Genet C. 2011;157 C(1):63–71. https://doi.org/10.1002/ajmg.c.30291.CrossRef

59.

Oguni T, Tomatsu S, Tanaka M, Orii K, Fukao T, Watanabe J, Fukuda S, Notsu Y, Vu DC, Can TBN, Nagai A, Yamaguchi S, Taketani T, Gelb MH, Kobayashi H. Validation of Liquid Chromatography-Tandem Mass Spectrometry-based 5-Plex assay for Mucopolysaccharidoses. Int J Mol Sci. 2020;21(6):2025. https://doi.org/10.3390/ijms21062025.CrossRefPubMedPubMedCentral

60.

Pan P, Chen M, Zhang Z, Corte AD, Souza C, Giugliani R, Pan L, Qiu Y, Amaravadi L, Wu J. A novel LC-MS/MS assay to quantify dermatan sulfate in cerebrospinal fluid as a biomarker for mucopolysaccharidosis II. Bioanalysis. 2018;10(11):825–38. https://doi.org/10.4155/bio-2018-0025.CrossRefPubMed

61.

Parini R, Broomfield A, Cleary MA, De Meirleir L, Di Rocco M, Fathalla WM, Guffon N, Lampe C, Lund AM, Scarpa M, Tylki-Szymańska A, Zeman J. International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome. Acta Paediatr (Oslo Norway: 1992). 2018;107(12):2059–65. https://doi.org/10.1111/apa.14587.CrossRef

62.

Polo G, Gueraldi D, Giuliani A, Rubert L, Cazzorla C, Salviati L, Marzollo A, Biffi A, Burlina AP, Burlina AB. The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I. Clin Chem Lab Med. 2020;58(12):2063–72. https://doi.org/10.1515/cclm-2020-0064.CrossRefPubMed

63.

Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, Prosser LA, Rosé AM, Comeau AM, Tanksley S, Powell CM, Kemper AR. Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States. Genet Medicine: Official J Am Coll Med Genet. 2023;25(2):100330. https://doi.org/10.1016/j.gim.2022.10.012.CrossRef

64.

Rowan DJ, Tomatsu S, Grubb JH, Montaño AM, Sly WS. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. J Inherit Metab Dis. 2013;36(2):235–46. https://doi.org/10.1007/s10545-012-9522-x.CrossRefPubMed

65.

S T, Ma G, Om TI, Am P, Aa MHMSV-CTN, La FACMTEW, Ls B, Iv LRG, Gs S, Sg FMB, K., … A, N. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis. 2005;28(5). https://doi.org/10.1007/s10545-005-0069-y.

66.

Sanders KA, Gavrilov DK, Oglesbee D, Raymond KM, Tortorelli S, Hopwood JJ, Lorey F, Majumdar R, Kroll CA, McDonald AM, Lacey JM, Turgeon CT, Tucker JN, Tang H, Currier R, Isaya G, Rinaldo P, Matern D. A comparative effectiveness study of newborn screening methods for four lysosomal Storage disorders. Int J Neonatal Screen. 2020;6(2):44. https://doi.org/10.3390/ijns6020044.CrossRefPubMedPubMedCentral

67.

Saville JT, McDermott BK, Fletcher JM, Fuller M. Disease and subtype specific signatures enable precise diagnosis of the mucopolysaccharidoses. Genet Medicine: Official J Am Coll Med Genet. 2019;21(3):753–7. https://doi.org/10.1038/s41436-018-0136-z.CrossRef

68.

Sawamoto K, Stapleton M, Alméciga-Díaz CJ, Espejo-Mojica AJ, Losada JC, Suarez DA, Tomatsu S. Therapeutic options for mucopolysaccharidoses: current and emerging treatments. Drugs. 2019;79(10):1103–34. https://doi.org/10.1007/s40265-019-01147-4.CrossRefPubMed

69.

Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, Gelb MH, Turecek F. Identification of infants at risk for developing fabry, pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163(2):498–503. https://doi.org/10.1016/j.jpeds.2013.01.031.CrossRefPubMedPubMedCentral

70.

Scott CR, Elliott S, Hong X, Huang J-Y, Kumar AB, Yi F, Pendem N, Chennamaneni NK, Gelb MH. Newborn screening for mucopolysaccharidoses: results of a pilot study with 100 000 dried blood spots. J Pediatr. 2020;216:204–7. https://doi.org/10.1016/j.jpeds.2019.09.036.CrossRefPubMed

71.

Singh R, Chopra S, Graham C, Langer M, Ng R, Ullal AJ, Pamula VK. Emerging approaches for fluorescence-based newborn screening of Mucopolysaccharidoses. Diagnostics (Basel Switzerland). 2020;10(5):294. https://doi.org/10.3390/diagnostics10050294.CrossRefPubMed

72.

Spiewak J, Doykov I, Papandreou A, Hällqvist J, Mills P, Clayton PT, Gissen P, Mills K, Heywood WE. New perspectives in dried blood spot biomarkers for lysosomal Storage diseases. Int J Mol Sci. 2023;24(12):10177. https://doi.org/10.3390/ijms241210177.CrossRefPubMedPubMedCentral

73.

Stapleton M, Arunkumar N, Kubaski F, Mason RW, Tadao O, Tomatsu S. Clinical presentation and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2018;125(1–2):4–17. https://doi.org/10.1016/j.ymgme.2018.01.003.CrossRefPubMed

74.

Stapleton M, Kubaski F, Mason RW, Shintaku H, Kobayashi H, Yamaguchi S, Taketani T, Suzuki Y, Orii K, Orii T, Fukao T, Tomatsu S. Newborn screening for mucopolysaccharidoses: measurement of glycosaminoglycans by LC-MS/MS. Mol Genet Metabolism Rep. 2020;22:100563. https://doi.org/10.1016/j.ymgmr.2019.100563.CrossRef

75.

Sun X, Li L, Overdier KH, Ammons LA, Douglas IS, Burlew CC, Zhang F, Schmidt EP, Chi L, Linhardt RJ. Analysis of total human urinary glycosaminoglycan disaccharides by Liquid Chromatography-Tandem Mass Spectrometry. Anal Chem. 2015;87(12):6220–7. https://doi.org/10.1021/acs.analchem.5b00913.CrossRefPubMedPubMedCentral

76.

Tanaka N, Kida S, Kinoshita M, Morimoto H, Shibasaki T, Tachibana K, Yamamoto R. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS. Mol Genet Metab. 2018;125(1–2):53–8. https://doi.org/10.1016/j.ymgme.2018.07.013.CrossRefPubMed

77.

Taylor JL, Clinard K, Powell CM, Rehder C, Young SP, Bali D, Beckloff SE, Gehtland LM, Kemper AR, Lee S, Millington D, Patel HS, Shone SM, Woodell C, Zimmerman SJ, Bailey DB, Muenzer J. The North Carolina experience with mucopolysaccharidosis type I newborn screening. J Pediatr. 2019;211:193–e2002. https://doi.org/10.1016/j.jpeds.2019.04.027.CrossRefPubMed

78.

Tebani A, Abily-Donval L, Schmitz-Afonso I, Héron B, Piraud M, Ausseil J, Zerimech F, Gonzalez B, Marret S, Afonso C, Bekri S. Unveiling metabolic remodeling in mucopolysaccharidosis type III through integrative metabolomics and pathway analysis. J Translational Med. 2018;16(1):248. https://doi.org/10.1186/s12967-018-1625-1.CrossRef

79.

Tebani A, Abily-Donval L, Schmitz-Afonso I, Piraud M, Ausseil J, Zerimech F, Pilon C, Pereira T, Marret S, Afonso C, Bekri S. Analysis of mucopolysaccharidosis type VI through integrative functional metabolomics. Int J Mol Sci. 2019;20(2):446. https://doi.org/10.3390/ijms20020446.CrossRefPubMedPubMedCentral

80.

Tebani A, Schmitz-Afonso I, Abily-Donval L, Héron B, Piraud M, Ausseil J, Brassier A, De Lonlay P, Zerimech F, Vaz FM, Gonzalez BJ, Marret S, Afonso C, Bekri S. Urinary metabolic phenotyping of mucopolysaccharidosis type I combining untargeted and targeted strategies with data modeling. Clin Chim Acta. 2017;475:7–14. https://doi.org/10.1016/j.cca.2017.09.024.CrossRefPubMed

81.

Tomatsu S, Fujii T, Fukushi M, Oguma T, Shimada T, Maeda M, Kida K, Shibata Y, Futatsumori H, Montaño AM, Mason RW, Yamaguchi S, Suzuki Y, Orii T. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2013;110(1–2):42–53. https://doi.org/10.1016/j.ymgme.2013.06.007.CrossRefPubMedPubMedCentral

82.

Tomatsu S, Okamura K, Maeda H, Taketani T, Castrillon SV, Gutierrez MA, Nishioka T, Fachel AA, Orii KO, Grubb JH, Cooper A, Thornley M, Wraith E, Barrera LA, Laybauer LS, Giugliani R, Schwartz IV, Frenking GS, Beck M, Noguchi A. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis. 2005;28(2):187–202. https://doi.org/10.1007/s10545-005-5673-3.CrossRefPubMed

83.

Tomatsu S, Shimada T, Mason RW, Montaño AM, Kelly J, LaMarr WA, Kubaski F, Giugliani R, Guha A, Yasuda E, Mackenzie W, Yamaguchi S, Suzuki Y, Orii T. Establishment of glycosaminoglycan assays for mucopolysaccharidoses. Metabolites. 2014;4(3):655–79. https://doi.org/10.3390/metabo4030655.CrossRefPubMedPubMedCentral

84.

Tong F, Wang J, Xiao R, Wu B-B, Zou C-C, Wu D-W, Wang H, Zou H, Han L-S, Yang L, Zou L, Hei M-Y, Yang R-L, Yuan T-M, Wen W, Huang X-W, Gu X-F, Yang Y-L, Huang Y-L, Zhao Z-Y. Application of next generation sequencing in the screening of monogenic diseases in China, 2021: a consensus among Chinese newborn screening experts. World J Pediatrics: WJP. 2022;18(4):235–42. https://doi.org/10.1007/s12519-022-00522-8.CrossRefPubMed

85.

Trim PJ, Hopwood JJ, Snel MF. Butanolysis derivatization: improved sensitivity in LC-MS/MS quantitation of heparan sulfate in urine from mucopolysaccharidosis patients. Anal Chem. 2015;87(18):9243–50. https://doi.org/10.1021/acs.analchem.5b01743.CrossRefPubMed

86.

Verheyen S, Blatterer J, Speicher MR, Bhavani GS, Boons G-J, Ilse M-B, Andrae D, Sproß J, Vaz FM, Kircher SG, Posch-Pertl L, Baumgartner D, Lübke T, Shah H, Kaissi A, Girisha A, K. M., Plecko B. Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency. J Med Genet. 2022;59(10):957–64. https://doi.org/10.1136/jmedgenet-2021-108061.CrossRefPubMed

87.

Verma S, Pantoom S, Petters J, Pandey AK, Hermann A, Lukas J. A molecular genetics view on mucopolysaccharidosis type II. Mutat Res Reviews Mutat Res. 2021;788:108392. https://doi.org/10.1016/j.mrrev.2021.108392.CrossRef

88.

Wang D, Eadala B, Sadilek M, Chamoles NA, Turecek F, Scott CR, Gelb MH. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem. 2005;51(5):898–900. https://doi.org/10.1373/clinchem.2004.047167.CrossRefPubMed

89.

Wang D, Wood T, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem. 2007;53(1):137–40. https://doi.org/10.1373/clinchem.2006.077263.CrossRefPubMed

90.

Wang J, Bhalla A, Ullman JC, Fang M, Ravi R, Arguello A, Thomsen E, Tsogtbaatar B, Guo JL, Skuja LL, Dugas JC, Davis SS, Poda SB, Gunasekaran K, Costanzo S, Sweeney ZK, Henry AG, Harris JM, Henne KR, Astarita G. High-throughput Liquid Chromatography-Tandem Mass Spectrometry quantification of glycosaminoglycans as biomarkers of mucopolysaccharidosis II. Int J Mol Sci. 2020;21(15):5449. https://doi.org/10.3390/ijms21155449.CrossRefPubMedPubMedCentral

91.

Yi F, Hong X, Kumar AB, Zong C, Boons G-J, Scott CR, Turecek F, Robinson BH, Gelb MH. Detection of mucopolysaccharidosis III-A (Sanfilippo Syndrome-A) in dried blood spots (DBS) by tandem mass spectrometry. Mol Genet Metab. 2018;125(1–2):59–63. https://doi.org/10.1016/j.ymgme.2018.05.005.CrossRefPubMedPubMedCentral

92.

Zhang C, Gawri R, Lau YK, Spruce LA, Fazelinia H, Jiang Z, Jo SY, Scanzello CR, Mai W, Dodge GR, Casal ML, Smith LJ. Proteomics identifies novel biomarkers of synovial joint disease in a canine model of mucopolysaccharidosis I. Mol Genet Metab. 2023;138(2):107371. https://doi.org/10.1016/j.ymgme.2023.107371.CrossRefPubMedPubMedCentral

93.

Zhang H, Dickson PI, Stiles AR, Chen AH, Le SQ, McCaw P, Beasley J, Millington DS, Young SP. Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy. Clin Chim Acta. 2020;508:179–84. https://doi.org/10.1016/j.cca.2020.05.035.CrossRefPubMed

94.

Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020;9(1):1–9. https://doi.org/10.5582/irdr.2020.01011.CrossRefPubMedPubMedCentral

Title: Application of tandem mass spectrometry in the screening and diagnosis of mucopolysaccharidoses
Authors: Jing-Wen Li
Shao-Jia Mao
Yun-Qi Chao
Chen-Xi Hu
Yan-Jie Qian
Yang-Li Dai
Ke Huang
Zheng Shen
Chao-Chun Zou
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Neonatal Screening
Biomarkers
Published in: Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-024-03195-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Application of tandem mass spectrometry in the screening and diagnosis of mucopolysaccharidoses

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry

Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series

Father-to-daughter transmission in late-onset OTC deficiency: an underestimated mechanism of inheritance of an X-linked disease

Pragmatic skills in people with Williams syndrome: the perception of families

Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II

Clinical and genetic study of ABCB4 gene-related cholestatic liver disease in China: children and adults